Close Menu

non-small cell lung cancer

The companies are developing an EGFR mutant-selective inhibitor with a companion diagnostic that will select NSCLC patients with an EGFR mutation linked to resistance to drugs like Iressa and Tarceva.

In addition to several PGx studies presented at the conference, the International Association for the Study of Lung Cancer and the European Thoracic Oncology Platform's European EGFR Workshop Group proposed recommendations on EGFR mutation testing in NSCLC when patients are treated with AstraZeneca's Iressa.

At the European Lung Cancer Conference last week in Geneva, Biodesix presented data from a multi-center Phase III study that showed VeriStrat was able to identify NSCLC patients most likely to have a "significant survival benefit" from treatment with Tarceva.

The company said that the move will allow patients to use its miRNA test without having to undergo more invasive procedures to obtain tumor samples.

Ahead of a cost-effectiveness appraisal by UK's NICE, AstraZeneca is paying for EGFR mutation testing for non-small cell lung cancer patients to determine if they will benefit from treatment with Iressa. The genetic testing program is part of a patient access scheme the company has agreed to with the National Health Service to provide more granularity about the cost and value of the treatment.

Scientists from Case Western Reserve University and Fluidigm have demonstrated how the nanofluidic digital PCR platform can detect and quantify EGFR mutations at the single-molecule level from lung tumors, including FFPE samples.

GSK is conducting a Phase III study for a MAGE-A3-targeting therapeutic for the adjuvant treatment of melanoma. To receive the drug in the study, participants' tumors must be shown to express MAGE-A3 via a molecular test that Abbott is developing.

Abbott and GSK will develop and commercialize a PCR test for the MAGE-A3 biomarker using Abbott's m2000 automated real-time PCR system.

Clarient Insight Dx Pulmotype is a five-antibody immunohistochemistry test that the company said can be used to aid in the histological distinction between adenocarcinoma and squamous cell carcinoma in NSCLC tumor specimens.

Using gene expression data on nearly 800 non-small lung cancer samples from four previously published studies, a team of Duke University researchers has identified age- and sex-specific pathways linked to NSCLC recurrence risk.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.